Market Closed -
Nasdaq
21:00:00 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
20.89
USD
|
-1.60%
|
|
+16.44%
|
+90.95%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
753.2
|
565.1
|
694.3
|
1,951
|
-
|
-
|
Enterprise Value (EV)
1 |
472.4
|
213.2
|
375.9
|
1,799
|
1,951
|
1,951
|
P/E ratio
|
-13.4
x
|
-7.1
x
|
-6.97
x
|
-11.9
x
|
-10.9
x
|
-11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
170
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
170
x
|
EV / EBITDA
|
-11
x
|
-2.99
x
|
-3.33
x
|
-13.8
x
|
-10.6
x
|
-7.91
x
|
EV / FCF
|
-13.8
x
|
-3.66
x
|
-3.85
x
|
-18.9
x
|
-
|
-
|
FCF Yield
|
-7.23%
|
-27.3%
|
-26%
|
-5.28%
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
49,296
|
63,214
|
63,462
|
93,410
|
-
|
-
|
Reference price
2 |
15.28
|
8.940
|
10.94
|
20.89
|
20.89
|
20.89
|
Announcement Date
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
11.5
|
EBITDA
1 |
-
|
-42.94
|
-71.29
|
-112.8
|
-130.1
|
-184.8
|
-246.8
|
EBIT
1 |
-
|
-43.22
|
-71.66
|
-114.4
|
-141.1
|
-187.9
|
-229.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,993.75%
|
Earnings before Tax (EBT)
1 |
-
|
-42.81
|
-67.64
|
-100.2
|
-125.6
|
-177.3
|
-190.1
|
Net income
1 |
-17.12
|
-42.81
|
-67.64
|
-100.2
|
-131
|
-165.8
|
-190.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,652.89%
|
EPS
2 |
-0.1224
|
-1.140
|
-1.260
|
-1.570
|
-1.759
|
-1.914
|
-1.897
|
Free Cash Flow
1 |
-
|
-34.18
|
-58.18
|
-97.69
|
-95
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-13.01
|
-12.74
|
-14.74
|
-16.39
|
-18.16
|
-21.99
|
-25.51
|
-
|
-29
|
-33.38
|
-29.29
|
-30.47
|
-33.94
|
-36.41
|
-
|
EBIT
1 |
-13.08
|
-12.82
|
-14.83
|
-16.49
|
-18.26
|
-22.08
|
-25.7
|
-25.34
|
-29.45
|
-33.86
|
-33.63
|
-34.7
|
-36.59
|
-39.03
|
-35.61
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.95
|
-12.7
|
-14.66
|
-16.07
|
-17.5
|
-19.42
|
-22.84
|
-21.47
|
-25.71
|
-30.14
|
-30.13
|
-31
|
-33.32
|
-35.07
|
-35.61
|
Net income
1 |
-12.95
|
-12.7
|
-14.66
|
-16.07
|
-17.5
|
-19.42
|
-22.84
|
-21.47
|
-25.71
|
-30.14
|
-31.43
|
-32.5
|
-34.71
|
-36.5
|
-35.61
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2600
|
-0.2600
|
-0.3000
|
-0.3200
|
-0.3400
|
-0.3100
|
-0.3600
|
-0.3400
|
-0.4100
|
-0.4700
|
-0.3960
|
-0.4040
|
-0.4240
|
-0.4340
|
-0.5100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
24/02/22
|
11/05/22
|
04/08/22
|
03/11/22
|
23/02/23
|
11/05/23
|
10/08/23
|
09/11/23
|
22/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
281
|
352
|
318
|
152
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-34.2
|
-58.2
|
-97.7
|
-95
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-21.3%
|
-21.8%
|
-30.1%
|
-39.9%
|
-34.9%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-20.6%
|
-20.7%
|
-28.3%
|
-37.1%
|
-33%
|
-
|
Assets
1 |
-
|
208.2
|
326.2
|
353.6
|
352.7
|
502.1
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
5.55
|
5.75
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/21
|
24/02/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
20.89
USD Average target price
31.17
USD Spread / Average Target +49.19% Consensus |
1st Jan change
|
Capi.
|
---|
| +90.95% | 1.98B | | +22.56% | 46.4B | | -1.51% | 41.75B | | +48.83% | 41.37B | | -3.42% | 29.71B | | +10.13% | 26.01B | | -20.44% | 19.52B | | +26.45% | 12.43B | | -0.14% | 12.18B | | -0.47% | 12.13B |
Other Biotechnology & Medical Research
|